It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
![]() PFE 3 months ago Paid | Quarterly | $0.43 Per Share |
![]() PFE 5 months ago Paid | Quarterly | $0.42 Per Share |
![]() PFE 9 months ago Paid | Quarterly | $0.42 Per Share |
![]() PFE 11 months ago Paid | Quarterly | $0.42 Per Share |
![]() PFE 25 Jan 2024 Paid | Quarterly | $0.42 Per Share |
29 Apr 2025 29 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
29 Oct 2024 Date | | 0.62 Cons. EPS | 1.06 EPS |
30 Jul 2024 Date | | 0.46 Cons. EPS | 0.6 EPS |
![]() PFE 3 months ago Paid | Quarterly | $0.43 Per Share |
![]() PFE 5 months ago Paid | Quarterly | $0.42 Per Share |
![]() PFE 9 months ago Paid | Quarterly | $0.42 Per Share |
![]() PFE 11 months ago Paid | Quarterly | $0.42 Per Share |
![]() PFE 25 Jan 2024 Paid | Quarterly | $0.42 Per Share |
29 Apr 2025 29 Apr 2025 Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 0.49 Cons. EPS | 0.63 EPS |
28 Jan 2025 Date | | 0.49 Cons. EPS | - EPS |
29 Oct 2024 Date | | 0.62 Cons. EPS | 1.06 EPS |
30 Jul 2024 Date | | 0.46 Cons. EPS | 0.6 EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Dr. Albert Bourla D.V.M., Ph.D. CEO | NYSE Exchange | US7170811035 ISIN |
US Country | 88,000 Employees | 24 Jan 2025 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.